There is no particular drug licensed by regulatory bodies (such as the United States Food and Drug Administration or the European Medicines Agency) for the treatment of secondary progressive multiple sclerosis (SPMS). However, depending on specific patient features and disease progression, several disease-modifying treatments (DMTs) licensed for relapsing forms of multiple sclerosis (MS) may be evaluated for use in SPMS.
It’s crucial to remember that the MS treatment landscape is always changing, and new drugs and treatment techniques may have surfaced since my previous update. To obtain the most up-to-date and accurate information on possible treatment options for secondary progressive MS, it is suggested that you speak with a neurologist or healthcare professional who specializes in treating MS.
Working together with a healthcare practitioner to build a treatment plan that fits the particular requirements and circumstances of the individual is vital if you or someone you know has SPMS. The healthcare professional can weigh the advantages and dangers of various treatment choices, taking into account factors such as illness progression, medical history, and probable prescription side effects.